BioCryst (BCRX) Investors: H.C. Wainwright Reiterates Buy Rating, Sees $10.0/Share; Generac Holdings (GNRC) Shorts Lowered By 0.66%

January 23, 2018 - By Adrian Mccoy

Among 14 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. BioCryst Pharmaceuticals has $16 highest and $2 lowest target. $7.20’s average target is 35.34% above currents $5.32 stock price. BioCryst Pharmaceuticals had 33 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Thursday, November 2 by RBC Capital Markets. The stock has “Buy” rating by H.C. Wainwright on Friday, May 26. The company was downgraded on Tuesday, February 9 by JP Morgan. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Market Outperform” rating given on Friday, December 16 by JMP Securities. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Outperform” rating given on Tuesday, January 2 by RBC Capital Markets. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Overweight” rating by JP Morgan on Wednesday, September 6. On Tuesday, August 8 the stock rating was maintained by Noble Financial with “Buy”. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Buy” rating by J.P. Morgan on Wednesday, September 6. Jefferies upgraded the stock to “Buy” rating in Wednesday, January 6 report. The firm earned “Overweight” rating on Friday, August 12 by PiperJaffray.

Generac Holdings Incorporated (NYSE:GNRC) had a decrease of 0.66% in short interest. GNRC’s SI was 4.56 million shares in January as released by FINRA. Its down 0.66% from 4.59M shares previously. With 455,900 avg volume, 10 days are for Generac Holdings Incorporated (NYSE:GNRC)’s short sellers to cover GNRC’s short positions. The SI to Generac Holdings Incorporated’s float is 7.46%. The stock increased 0.12% or $0.06 during the last trading session, reaching $51.7. About 300,406 shares traded. Generac Holdings Inc. (NYSE:GNRC) has risen 0.51% since January 23, 2017 and is uptrending. It has underperformed by 16.19% the S&P500.

Since August 1, 2017, it had 0 insider buys, and 4 selling transactions for $1.60 million activity. 20,000 shares valued at $980,511 were sold by Jagdfeld Aaron on Tuesday, January 2.

Generac Holdings Inc. designs, manufactures, and sells power generation equipment and other engine powered products for the residential, light commercial, and industrial markets worldwide. The company has market cap of $3.21 billion. The firm offers engines, alternators, transfer switches, and other components fueled by natural gas, liquid propane, gasoline, diesel, and bi-fuel. It has a 27.18 P/E ratio. It also provides residential automatic standby generators ranging in output from 6kW to 60kW; air-cooled engine residential standby generators ranging from 6kW to 20kW; liquid-cooled engine generators with outputs ranging from 22kW to 60kW; cellular remote monitoring system for home standby generators; and industrial diesel generators ranging in sizes up to 3,250kW.

Among 10 analysts covering Generac Holdings (NYSE:GNRC), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Generac Holdings had 28 analyst reports since August 7, 2015 according to SRatingsIntel. As per Friday, September 8, the company rating was maintained by Stifel Nicolaus. Canaccord Genuity maintained the stock with “Hold” rating in Monday, July 31 report. The company was upgraded on Thursday, October 29 by Bank of America. On Wednesday, October 4 the stock rating was maintained by Robert W. Baird with “Buy”. Canaccord Genuity maintained Generac Holdings Inc. (NYSE:GNRC) on Thursday, October 26 with “Hold” rating. KeyBanc Capital Markets upgraded the stock to “Overweight” rating in Monday, October 2 report. The stock of Generac Holdings Inc. (NYSE:GNRC) has “Hold” rating given on Wednesday, February 15 by Canaccord Genuity. The firm earned “Hold” rating on Thursday, August 3 by Oppenheimer. The company was upgraded on Friday, September 15 by Bank of America. Canaccord Genuity maintained the shares of GNRC in report on Monday, April 24 with “Hold” rating.

Investors sentiment increased to 1.42 in Q3 2017. Its up 0.68, from 0.74 in 2017Q2. It improved, as 18 investors sold Generac Holdings Inc. shares while 63 reduced holdings. 57 funds opened positions while 58 raised stakes. 58.60 million shares or 1.34% more from 57.82 million shares in 2017Q2 were reported. Susquehanna Gru Llp reported 0% in Generac Holdings Inc. (NYSE:GNRC). Schroder Mngmt Gp holds 0.05% or 573,869 shares. Tower Limited Liability Com (Trc) has 0.03% invested in Generac Holdings Inc. (NYSE:GNRC) for 7,029 shares. Parametric Port Associate Ltd Liability reported 0.01% of its portfolio in Generac Holdings Inc. (NYSE:GNRC). Massachusetts-based Boston Prtn has invested 0.01% in Generac Holdings Inc. (NYSE:GNRC). Moreover, Manufacturers Life Ins Co The has 0% invested in Generac Holdings Inc. (NYSE:GNRC). Moreover, Frontier Management Communication Ltd Company has 0.02% invested in Generac Holdings Inc. (NYSE:GNRC). Alliancebernstein L P has invested 0.01% of its portfolio in Generac Holdings Inc. (NYSE:GNRC). Proshare Advsrs Llc reported 4,587 shares. Loomis Sayles And Limited Partnership holds 0.07% of its portfolio in Generac Holdings Inc. (NYSE:GNRC) for 652,469 shares. Moreover, Impax Asset Mngmt Limited has 1.08% invested in Generac Holdings Inc. (NYSE:GNRC) for 771,325 shares. New York State Teachers Retirement Systems holds 5,400 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% stake. Employees Retirement Of Ohio holds 0% or 5,827 shares. Fil reported 25,773 shares.

The stock decreased 4.83% or $0.27 during the last trading session, reaching $5.32. About 5.20M shares traded or 356.83% up from the average. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since January 23, 2017 and is uptrending. It has outperformed by 58.38% the S&P500.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.01, from 1.68 in 2017Q2. It is positive, as 12 investors sold BioCryst Pharmaceuticals, Inc. shares while 24 reduced holdings. 28 funds opened positions while 33 raised stakes. 79.80 million shares or 20.47% more from 66.24 million shares in 2017Q2 were reported. Wells Fargo And Mn owns 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 96,671 shares. Los Angeles Cap Management & Equity Research Inc holds 0% or 25,170 shares in its portfolio. Proshare Advisors Lc has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Retail Bank Of New York Mellon has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Aqr Mngmt Ltd Liability Com reported 66,119 shares or 0% of all its holdings. Moreover, Arrowmark Colorado Hldg Limited Liability has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 12,019 shares. Moreover, Citadel Ltd Liability has 0.01% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 1.40 million shares. Great Point Prtnrs Limited Liability Corp holds 1.67% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 1.64 million shares. State Street has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). California State Teachers Retirement Systems has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 128,045 shares. Janney Montgomery Scott Limited Liability Corporation invested in 31,335 shares. Advisory Services Lc holds 6,500 shares or 0% of its portfolio. Venbio Select Advisor Lc stated it has 1.78 million shares or 0.72% of all its holdings. Jennison Limited Liability Com holds 3.08M shares. Pillar Pacific Capital Limited Liability reported 0.01% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Since September 18, 2017, it had 0 insider purchases, and 1 sale for $294,035 activity. Shares for $294,035 were sold by Cohen Fred E on Monday, September 18.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $523.51 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.

Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on February, 26. They expect $-0.15 EPS, down 150.00% or $0.09 from last year’s $-0.06 per share. After $-0.18 actual EPS reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -16.67% EPS growth.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>